Cencora
Conshohocken
PA
United States
411 articles about Cencora
-
Cencora Announces Leadership Succession Plan - March 12, 2024
3/12/2024
Cencora, Inc. announced that Steven H. Collis will retire as President and Chief Executive Officer of the Company and transition to the role of Executive Chair of the Cencora Board of Directors, effective October 1, 2024.
-
Cencora’s FormularyDecisions Launches Payer Resource for Cell and Gene Therapy Products
2/8/2024
With the increasing number of cell and gene therapy products in clinical development, Cencora’s FormularyDecisions launched a new resource designed to provide healthcare payers with centralized access to information on approved therapies and products in the pipeline.
-
Cencora Closes $500 Million Senior Notes Offering
2/7/2024
Cencora, Inc. announced the closing of its public offering of $500 million aggregate principal amount of its 5.125% Senior Notes due 2034, in an underwritten registered public offering.
-
Cencora Releases 2023 ESG Report
2/7/2024
Cencora, a global healthcare company, released its 2023 Environmental, Social and Governance Report.
-
Cencora Prices $500 Million 5.125% Senior Notes Due 2034
2/5/2024
Cencora, Inc. announced that it priced $500 million aggregate principal amount of its 5.125% Senior Notes due 2034, in an underwritten registered public offering.
-
Cencora Reports Fiscal 2024 First Quarter Results
1/31/2024
Cencora, Inc. reported that in its fiscal year 2024 first quarter ended December 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion.
-
Cencora Announces Date and Time for First Quarter Fiscal 2024 Earnings Release
1/4/2024
Cencora, Inc. announced that it plans to release its results for the First Quarter of Fiscal 2024 on Wednesday, January 31, 2024, prior to the opening of trading on the New York Stock Exchange.
-
Sapphiros and Cencora, formerly AmerisourceBergen Corporation, Enter into Distribution Agreement
11/22/2023
Sapphiros is proud to announce it has entered into a distribution agreement with Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation.
-
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
11/10/2023
Cencora, Inc., formerly AmerisourceBergen Corporation, announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $250 million in concurrence with Walgreens Boots Alliance’s entry into certain variable pre-paid forward transactions executed in reliance on Rule 144 under the Securities Act of 1933, as amended.
-
Cencora Reports Fiscal 2023 Fourth Quarter and Year End Results
11/2/2023
Cencora, Inc., formerly AmerisourceBergen Corporation, reported that in its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion.
-
Cencora, Formerly AmerisourceBergen, Announces Date and Time for Fourth Quarter Fiscal 2023 Earnings Release
10/2/2023
Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation, today announced that it plans to release its results for the Fourth Quarter of Fiscal 2023 on Thursday, November 2, 2023, prior to the opening of trading on the New York Stock Exchange.
-
AmerisourceBergen Announces Intent to Change Name to Cencora
1/24/2023
AmerisourceBergen (NYSE: ABC) today announced its intent to change its name to better reflect its bold vision and purpose-driven approach to creating healthier futures. AmerisourceBergen intends to become Cencora.
-
AmerisourceBergen Kicks Off Strategic Relationship with Civica
1/23/2023
Starting today, global healthcare company AmerisourceBergen will serve as Civica, Inc.’s (Civica) exclusive distribution partner and provide supply chain support for Civica’s products and a best-in-class customer experience for Civica members.
-
AmerisourceBergen Completes Acquisition of PharmaLex
1/3/2023
AmerisourceBergen Corporation (NYSE: ABC) today announced the completion of its acquisition of PharmaLex Holding GmbH.
-
AmerisourceBergen Announces Common Share Repurchase From Walgreens Boots Alliance
12/9/2022
AmerisourceBergen Corporation announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $200 million in concurrence with Walgreens Boots Alliance’s sale of AmerisourceBergen shares pursuant to Rule 144.
-
AmerisourceBergen Elects Redonda Miller, M.D., to its Board of Directors
11/16/2022
AmerisourceBergen Corporation announced that its Board of Directors has elected Redonda Miller, M.D., 56, as a new independent director, effective January 1, 2023.
-
AmerisourceBergen Announces Secondary Public Offering of Common Shares and Common Share Repurchase
11/7/2022
AmerisourceBergen Corporation announced a secondary public offering of 10 million shares of common stock of the Company held by Walgreens Boots Alliance Holdings LLC.
-
AmerisourceBergen Reports Fiscal 2022 Fourth Quarter and Year End Results
11/3/2022
AmerisourceBergen Corporation reported that in its fiscal year 2022 fourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion.
-
Opthalmology Space Gains Clarity with Partnerships & Acquisitions by Outlook & Visus Therapeutics
9/28/2022
A cloudy ophthalmic space got a little clearer Wednesday with the two collaborations by Visus Therapeutics and Outlook Therapeutics, now preparing for FDA approval. -
AmerisourceBergen Announces Date and Time for Fourth Quarter Fiscal 2022 Earnings Release
9/28/2022
AmerisourceBergen Announces Date and Time for Fourth Quarter Fiscal 2022 Earnings Release.